Mirum Pharmaceuticals said its VISTAS Phase 2b study of Volixibat met the primary endpoint in patients with primary sclerosing cholangitis (PSC). The result supports the drug’s potential as a first treatment for PSC and is a meaningful clinical de-risking event for the program. The announcement is positive for Mirum, though the article provides no trial data, approval timeline, or commercial figures.
Mirum Pharmaceuticals said its VISTAS Phase 2b study of Volixibat met the primary endpoint in patients with primary sclerosing cholangitis (PSC). The result supports the drug’s potential as a first treatment for PSC and is a meaningful clinical de-risking event for the program. The announcement is positive for Mirum, though the article provides no trial data, approval timeline, or commercial figures.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
